India  

Experts question Covaxin’s high private market price as R&D was govt subsidised

IndiaTimes Friday, 11 June 2021
Experts have questioned the rationale of high prices of Covaxin since it is based on an established technology, is domestically-produced, and it’s R&D has been part-subsidised by the Centre. Other vaccines like polio and hepatitis B using a similar technology platform, are affordable due to large volumes and economies of scale, a strategy which should have been followed early-on in the case of Covaxin, they said.
0
shares
ShareTweetSavePostSend
 
Video Credit: Oneindia - Published
News video: Vaccine prices at private hospitals capped by centre| Covidshield| Covaxin| Sputnik V| Oneindia News

Vaccine prices at private hospitals capped by centre| Covidshield| Covaxin| Sputnik V| Oneindia News 02:04

A day after Prime Minister Narendra Modi capped the service charge of vaccines administered by private hospitals at Rs 150, the Centre on Tuesday fixed the maximum price for Covid vaccines to be given by private players. Under the new circular, the price of Covishield has been fixed at Rs 780,...

💡 newsR Knowledge: Other News Mentions

Covaxin Covaxin Vaccine against COVID-19

CDSCO expert panel recommends nod to study on mixing doses of Covaxin, Covishield

An expert panel of India's central drug authority on Thursday recommended granting permission to the Christian Medical College (CMC) in Vellore for conducting a..
IndiaTimes

Brazil's Anvisa provisionally suspends authorisation for exceptional import of 4 million Covaxin doses

After closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotech’s Covaxin, Brazil’s health regulator Anvisa..
IndiaTimes

After suspending Covaxin clinical trials, Brazil closes EUA request

After suspending the clinical trials of Covaxin following the termination of Bharat Biotech's MoU with its Brazilian partner Precisa Medicamentos, Brazil’s..
IndiaTimes

COVID-19 vaccine for children likely by September: AIIMS Chief

In view of a probable third wave of the pandemic, vaccination trials on children have been underway in India with Covaxin and Zydus Cadila's ZyCov-D.
DNA

You Might Like